Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512460 · ClinicalTrials.gov registry record · Phase 1
RTA 744 Injection in Patients With Leptomeningeal Disease
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00512460: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00512460 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00512460, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
1. The primary objectives of this study are: 1. To determine the tolerability of RTA 744 Injection in patients with leptomeningeal disease (LMD) secondary to any type of primary tumor. 2. In a selected group of 6-10 patients who will receive RTA 744 at or near the maximum tolerated dose (MTD), to characterize the multiple-dose pharmacokinetics of RTA 744 in plasma and CSF. 2. The secondary objectives of this study are: 1. To document any potential antitumor activity of RTA 744 in this patient population. 2. To correlate pharmacokinetic information with clinical (efficacy and safety) responses, as a possible help in selecting appropriate doses for later studies.
Interventions
- DRUG RTA 744
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512460
The ClinicalTrials.gov registry entry for NCT00512460 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RTA 744 is the first listed.
NCT00512460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512460 about?
NCT00512460 is a clinical study titled "RTA 744 Injection in Patients With Leptomeningeal Disease". 1. The primary objectives of this study are: 1. To determine the tolerability of RTA 744 Injection in patients with leptomeningeal disease (LMD) secondary to any type of primary tumor. 2. In a selected group of 6-10 patients who will receive RTA 744 at or near the maximum tolerated dose (MTD)...
What is the current status of trial NCT00512460?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2006-09. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00512460?
The interventions under investigation include: RTA 744 (DRUG).
Who is sponsoring clinical trial NCT00512460?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.